STATEN ISLAND, N.Y., May 16, 2023 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase…Read More
Acurx Pharmaceuticals Inc Announces Pricing of 40 Million Registered Direct Offering MarketScreener
